Spyre Therapeutics, Inc.

DB:3920 Stock Report

Market Cap: €1.3b

Spyre Therapeutics Management

Management criteria checks 0/4

Spyre Therapeutics' CEO is Cameron Turtle, appointed in Oct 2023, has a tenure of 1.33 years. total yearly compensation is $16.17M, comprised of 1.7% salary and 98.3% bonuses, including company stock and options. directly owns 1.27% of the company’s shares, worth €16.38M. The average tenure of the management team and the board of directors is 1.3 years and 1.7 years respectively.

Key information

Cameron Turtle

Chief executive officer

US$16.2m

Total compensation

CEO salary percentage1.7%
CEO tenure1.3yrs
CEO ownership1.3%
Management average tenure1.3yrs
Board average tenure1.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Cameron Turtle's remuneration changed compared to Spyre Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$215m

Jun 30 2024n/an/a

-US$186m

Mar 31 2024n/an/a

-US$364m

Dec 31 2023US$16mUS$273k

-US$339m

Compensation vs Market: Cameron's total compensation ($USD16.17M) is above average for companies of similar size in the German market ($USD1.54M).

Compensation vs Earnings: Insufficient data to compare Cameron's compensation with company performance.

CEO

Cameron Turtle (34 yo)

1.3yrs

Tenure

US$16,174,660

Compensation

Dr. Cameron Turtle, D.Phil, Ph D, joined Spyre Therapeutics, Inc. as Chief Operating Officer in June 2023 and served until November 28, 2023 and serves as its Chief Executive Officer and Director at Spyre...

Leadership Team

NamePositionTenureCompensationOwnership
Cameron Turtle
CEO & Director1.3yrsUS$16.17m1.27%
€ 16.4m
Scott Burrows
Chief Financial Officer1.4yrsUS$7.55m0.026%
€ 333.6k
Heidy King-Jones
Chief Legal Officer & Corporate Secretary1.4yrsUS$6.93m0%
€ 0
Janet Gunzner-Toste
Senior Vice President of Operationsno datano datano data
Brian Connolly
Chief Technical Officer1.3yrsno datano data
Eric McIntyre
Vice President of Finance & Investor Relationsno datano datano data
James Myers
Vice President of Quality & Complianceno datano datano data
Justin LaFountaine
Senior Vice President of Corporate Developmentno datano datano data
Melissa Cooper
Senior Vice President of Peopleno datano datano data
James Kastenmayer
Consultant1.8yrsUS$865.79kno data
Joshua Friedman
Senior Vice President of Clinical Development1.3yrsno datano data
Deanna Nguyen
Senior Vice President of Clinical Development1.3yrsno datano data

1.3yrs

Average Tenure

44yo

Average Age

Experienced Management: 3920's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Cameron Turtle
CEO & Director1.3yrsUS$16.17m1.27%
€ 16.4m
Daniel Von Hoff
Member of Scientific Advisory Board8.4yrsno datano data
Matthew Vander Heiden
Member of Scientific Advisory Board8.4yrsno datano data
Keith Flaherty
Member of Scientific Advisory Board8.4yrsno datano data
Jeffrey Albers
Independent Chairman of the Board1.3yrsUS$433.57k0.047%
€ 599.9k
Arthur Frankel
Member of Scientific Advisory Board8.4yrsno datano data
Wayne Klohs
Member of Scientific Advisory Board8.4yrsno datano data
Tomas Kiselak
Independent Director1.7yrsUS$658.43k0.69%
€ 8.9m
Laurie Stelzer
Independent Director1.3yrsUS$434.38k0%
€ 0
Michael Henderson
Independent Director1.7yrsUS$660.78k0.18%
€ 2.3m
Peter Harwin
Independent Director1.7yrsUS$661.28k0.69%
€ 8.9m
Sandra Milligan
Directorless than a yearno datano data

1.7yrs

Average Tenure

53yo

Average Age

Experienced Board: 3920's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/09 01:24
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Spyre Therapeutics, Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Mayur SomaiyaBMO Capital Markets Equity Research
Julian HarrisonBTIG